hackint0sh/New-Dataset huggingface dataset:
Participants will be asked to complete a baseline assessment of mood, substance use, and psychophysiology. Participants will then completed ecological momentary assessments (EMA) via smartphone technology 4 times a day for \~ 28 days (the day following the baseline assessment until the 3rd intervention session). Participants will complete one 45 minute - 1 hour intervention each week for 3 weeks (either the IMPROVE or PHET intervention, pending randomization). Following the last intervention session, participants will return to the lab to complete a post-intervention assessment that mirrors the baseline assessment and then complete follow-up surveys 1- and 3-months post intervention. conditions: Anxiety conditions: Substance Use Disorders studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Participants will be randomized to receive one of two possible interventions. primaryPurpose: PREVENTION masking: SINGLE maskingDescription: Raters completing the outcome assessments will be blind to condition. whoMasked: OUTCOMES_ASSESSOR count: 40 type: ESTIMATED name: IMPROVE name: PHET measure: Intolerance of Uncertainty-12 Scale measure: Anxiety Sensitivity-3 Scale measure: PROMIS Anxiety Short Form measure: Timeline Followback measure: Desire for Drug Questionnaire measure: Penn Alcohol Craving Scale measure: Hyperkatifeia Interference Scale - Alcohol Version. measure: Clinical Institute Withdrawal Assessment Alcohol Scale Revised. measure: Hyperkatifeia Interference Scale - Opioid Version. measure: Subjective Opiate Withdrawal Scale measure: NPU Threat Task measure: Straw Breathing Avoidance Task measure: Emotion Picture Paradigm Task sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ohio State University Department of Psychiatry and Behavioral Health city: Columbus state: Ohio zip: 43062 country: United States name: Nicholas P Allan, PhD role: CONTACT lat: 39.96118 lon: -82.99879 hasResults: False
nctId: NCT06299644 id: 2023P003282 briefTitle: Endoscopic Sleeve Gastroplasty Technique Comparison for Weight Loss overallStatus: NOT_YET_RECRUITING date: 2025-05-01 date: 2026-07-01 date: 2026-12-31 date: 2024-03-08 date: 2024-03-08 name: Brigham and Women's Hospital class: OTHER name: Endo Tools Therapeutics S.A. briefSummary: The Investigators propose suture plication placement at the distal gastric body drives a significant portion of weight loss in endoscopic sleeve and sutures only need to be placed in the distal gastric body. Therefore, in this pilot study, the investigators aim to compare "belt" with "belt and suspenders" plication pattern using the Endomina system to determine percent total weight loss. conditions: Obesity conditions: Obesity, Morbid conditions: Metabolic Disease conditions: Weight, Body studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 10 type: ESTIMATED name: Endoscopic Sleeve Gastroplasty - Belt and Suspenders name: Endoscopic Sleeve Gastroplasty - Belt measure: Percent TWL (%TWL) measure: Adverse Events measure: Gastric Emptying measure: Number of participants with improvement in fasting glucose measure: Number of participants with improvement in Hemoglobin A1c (HgA1c %) measure: Improvement in fasting lipids profile measure: Number of participants with a change in ghrelin hormone values measure: Obesity-related comorbidities - hypertension measure: Obesity-related comorbidities - change in hypertension concomitant medications measure: Obesity-related comorbidities - change in pre-diabetes/diabetes concomitant medications measure: Obesity-related comorbidities - pre-diabetes/diabetes measure: Obesity-related comorbidities - gastroesophageal reflux (GERD) sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Brigham and Women's Hospital city: Boston state: Massachusetts zip: 02115 country: United States lat: 42.35843 lon: -71.05977 hasResults: False
nctId: NCT06299631 id: RECHMPL23_0187 briefTitle: Endoscopic Relapse Risks Evaluation After Ileocolic Resection for Crohn's Disease acronym: RIC-1 overallStatus: COMPLETED date: 2015-01 date: 2023-06 date: 2023-12 date: 2024-03-08 date: 2024-03-08 name: University Hospital, Montpellier class: OTHER name: Carémeau University Hospital, Nîmes briefSummary: Aim of the study:
Endoscopic recurrence (defined as \> i2 lesions according to Rutgeerts classification) 6 months after surgery conditions: Crohn's Disease studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 133 type: ACTUAL name: Ileocolic resection measure: Endoscopic recurrence rate measure: Resection margins measure: Length of resected specimen measure: Duration of surgery measure: Intra-operative blood loss measure: Postoperative morbidity rate measure: Mortality rate measure: Myenteric plexitis measure: Number of inflammatory cells in myenteric plexuses sex: ALL minimumAge: 18 Years maximumAge: 99 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Montpellier University Hospital city: Montpellier zip: 34295 country: France lat: 43.61092 lon: 3.87723 hasResults: False
nctId: NCT06299618 id: ENIGMA-I briefTitle: Environmental Influence on Mental Illness Via Modifications of Genomes and Metabolomes in Adolescents With Autism acronym: ENIGMA-I overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-05 date: 2025-12 date: 2024-03-08 date: 2024-03-08 name: University College Cork class: OTHER name: University of Southampton name: Carol Davila University of Medicine and Pharmacy name: Microlink PC UK LTE name: Engineering Ingegneria Informatica SpA name: MEDEA SRL name: ORTHOKEY ITALIA SRL briefSummary: The aim of the study is to enrich the understanding of the physiological mechanisms that predispose autistic adolescents to mental illness. It will inform a possible pathway and biomarker handprint of mental illness severity and prognosis to formulate a neurobiologically informed personalization strategy that could be applied for selecting appropriate Evidence Based Intervention (EBI) for treating an adolescent formally diagnosed with Autism. conditions: Autism conditions: Autism Spectrum Disorder studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 400 type: ESTIMATED measure: Symptoms of anxiety measure: Symptoms of anxiety measure: Symptoms of depression measure: Symptoms of depression measure: Attention-Deficit/Hyperactivity measure: Sleep disturbance measure: Physical Activity measure: Symptoms of Mental Health Disorders measure: Cognitive Assessment measure: Nutritional Assessment measure: Heart Rate measure: Respiratory Rate measure: Genotype measure: DNA Methylation measure: Hormone Levels measure: Metabolomic Profile sex: ALL minimumAge: 11 Years maximumAge: 15 Years stdAges: CHILD facility: University College Cork city: Cork country: Ireland name: Deirdre Murray, PhD role: CONTACT email: enigma@ucc.ie name: Jean Conway, Masters role: CONTACT email: ethereal@ucc.ie lat: 51.89797 lon: -8.47061 facility: University of Medicine and Pharmacy Carol Davila Bucharest city: Bucharest country: Romania lat: 44.43225 lon: 26.10626 facility: University of Southampton city: Southampton country: United Kingdom name: Samuele Cortese, MD role: CONTACT name: Koushik Maharatna, PhD role: CONTACT email: km3@ecs.soton.ac.uk lat: 50.90395 lon: -1.40428 hasResults: False
nctId: NCT06299605 id: SHARE2401 briefTitle: Triple Versus Quadruple Therapy for the Eradication of Helicobacter Pylori acronym: SHARE2401 overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2024-10 date: 2024-11 date: 2024-03-08 date: 2024-03-08 name: Shandong University class: OTHER name: Binzhou Maternal and Child Health Hospital name: Zibo Maternal and Child Health Hospital name: Zaozhuang Municipal Hospital name: Linyi Yizhou Hospital name: Feicheng Municipal People's Hospital briefSummary: The study aimed to compare the efficacy and safety of 7-day and 14-day vonoprazan-amoxicillin-tetracycline triple therapy with 14-day vonoprazan-amoxicillin-tetracycline-bismuth quadruple therapy for the eradication of Helicobacter pylori. Subjects were randomized to receive the intervention and were reviewed by 13C-urea breath test after 6 weeks. The eradication rates, adverse reaction rates and patient adherence were calculated. conditions: Helicobacter Pylori Infection studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 375 type: ESTIMATED name: Vonoprazan-Amoxicillin-Tetracycline-Bismuth quadruple regimen for 14 days name: Vonoprazan-Amoxicillin-Tetracycline triple regimen for 14 days name: Vonoprazan-Amoxicillin-Tetracycline triple regimen for 7 days measure: Eradication rate measure: Rate of adverse reactions measure: Patient compliance sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06299592 id: 2023-1626 id: 1RF1AG082215-01 type: NIH link: https://reporter.nih.gov/quickSearch/1RF1AG082215-01 id: A538900 type: OTHER domain: UW- Madison id: SMPH/PSYCHIATRY/PSYCHIATRY type: OTHER domain: UW- Madison id: Protocol Version 10/15/2023 type: OTHER domain: UW- Madison briefTitle: Comparison of Microglial Activation in Severe Asthma and Healthy Controls acronym: MAIA-SC overallStatus: RECRUITING date: 2024-03-06 date: 2028-08 date: 2028-08 date: 2024-03-08 date: 2024-03-27 name: University of Wisconsin, Madison class: OTHER name: National Institute on Aging (NIA) briefSummary: The goal of this clinical trial is to learn about how asthma influences brain function. The main questions it aims to answer are:
Researchers will compare results between participants with asthma, and participants who do not have asthma. conditions: Asthma studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 100 type: ESTIMATED name: PET/MRI using [18F]FEPPA tracer measure: Binding of [18F]-FEPPA measure: How activated microglia correspond to immune biomarkers in lung and blood measure: Relationship between activated microglia and cognitive function measure: Relationship between activated microglia and psychological symptoms sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Center for Healthy Minds status: RECRUITING city: Madison state: Wisconsin zip: 53703 country: United States name: Janelle Grogan role: CONTACT phone: 608-263-0524 email: jegrogan@medicine.wisc.edu name: Melissa Rosenkranz, PhD role: PRINCIPAL_INVESTIGATOR lat: 43.07305 lon: -89.40123 hasResults: False
nctId: NCT06299579 id: WG-GD11-III-01 briefTitle: GD-11 for Injection in the Treatment of Acute Ischemic Stroke overallStatus: RECRUITING date: 2024-02-29 date: 2025-02-22 date: 2025-12-31 date: 2024-03-08 date: 2024-03-15 name: Beijing Tiantan Hospital class: OTHER name: Jiangsu Wangao Pharmaceutical Co. ltd briefSummary: Phase III Clinical Trial of GD-11 for Injection in the Treatment of Acute Ischemic Stroke - A Multi-Center, Randomized, Double-Blind, Parallel, Placebo-Controlled Phase III Clinical Study with the primary objective of evaluation of the efficacy and safety of GD-11 for injection in the treatment of acute ischemic stroke patients within 48 hours. The subject has a clinical diagnosis of acute ischemic stroke, within 48 hours from stroke onset to start of study treatment, with a National Institutes of Health Stroke Scale (NIHSS) between 6 and 20, had a total score of upper and lower limbs on motor deficits ≥ 2. The primary outcome is the proportion of subjects with mRS score ≤ 1 at 90 days after treatment. conditions: Acute Ischemic Stroke studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: This trial is designed as a multicenter, randomized, double-blind, placebo-parallel controlled trial using a multicenter, randomized, double-blind, placebo-parallel controlled trial design. Subjects are randomly assigned in a 1:1 ratio and random number tables are generated using SAS（Statistics Analysis System）software. primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 980 type: ESTIMATED name: GD-11 for injection test group name: Placebo control group measure: Proportion of subjects with mRS score ≤1 on 90th day of treatment sex: ALL minimumAge: 18 Years maximumAge: 81 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Beijing Tiantan Hospital Capital Medical University Beijing status: NOT_YET_RECRUITING city: Beijing state: Beijing zip: 100000 country: China name: Yongjun Wang role: CONTACT email: yongjunwang111@aliyun.com name: Yongjun Wang role: PRINCIPAL_INVESTIGATOR lat: 39.9075 lon: 116.39723 facility: Linfen Central Hospital status: RECRUITING city: Shangxi state: Linfen City zip: 041099 country: China name: hongguo Dai role: CONTACT email: daihongguo3199@163.com hasResults: False
nctId: NCT06299566 id: CF NGS briefTitle: Perceptions of the CF Screening Protocol Incorporating NGS overallStatus: COMPLETED date: 2022-01-19 date: 2023-02-28 date: 2023-02-28 date: 2024-03-08 date: 2024-03-08 name: King's College London class: OTHER name: University of Warwick name: Coventry University name: Barts & The London NHS Trust name: Cystic Fibrosis Trust briefSummary: Newborn bloodspot screening (from now on referred to as screening) for cystic fibrosis (CF) became part of the national screening programme in 2007. Screening for CF is also well established internationally. The current process works well but has some disadvantages: carrier reporting - which is not the intention of CF screening in the UK (\~200 pa); need for repeat samples which can be costly and contribute to parental worry (\~300 pa.); mutation panels not fully reflecting the ethnic diversity of the birth population; identification of children designated as CF screen positive, inconclusive diagnosis (CFSPID) which can cause uncertainty (\~20-30 pa).
4. Evaluate and learn from the exercise to inform future stakeholder engagement activities by the UK NSC and screening programmes. conditions: Cystic Fibrosis studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: PROSPECTIVE count: 150 type: ACTUAL measure: Focus groups/interviews/questionnaires exploring stakeholder views of the proposed CF screening protocol incorporating NGS. measure: Focus groups/interviews/questionnaires exploring stakeholder views on equivocal, carrier, false positives/negatives results, late onset/uncertain conditions measure: Q sorts used to develop data and materials FMCH and UK NSC can use to engage stakeholders measure: Surveys to explore principles of engagement for stakeholders sex: ALL minimumAge: 10 Years maximumAge: 99 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: King's College London city: London zip: SE5 9RS country: United Kingdom lat: 51.50853 lon: -0.12574 hasResults: False
nctId: NCT06299527 id: 01032024 briefTitle: Telerehabilitation in Patients With Fibromyalgia overallStatus: COMPLETED date: 2023-05-27 date: 2023-11-15 date: 2024-01-27 date: 2024-03-08 date: 2024-03-13 name: Marmara University class: OTHER briefSummary: Sixty-six FMS patients received the same exercise program for 8 weeks and divided, synchronous (n: 33), asynchronous (n: 33). Pain (Visual analog Scale, VAS), functional limitations and disabilities (Revised Fibromyalgia Impact Questionnaire, FEA), health-related quality of life (HRQol; Short Form-12, SF 12), catastrophizing (pain catastrophizing scale, PCS), anxiety and depression (Hospital Anxiety and Depression Scale, HAD), functional capacity (6-minute walking test, 6MWT), muscle strength (Arm curl test) joint position sense (Laser Cursor Assisted Angle Repetition Test, LI-RATT) were assessed at baseline, mid-treatment (week 4), end of treatment (week 8), and eight weeks after treatment (week 16). conditions: Fibromyalgia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 66 type: ACTUAL name: Exercise Program measure: Visual Analog Scale measure: Revised Fibromyalgia Impact Questionnaire measure: Pain Catastrophizing Scale measure: Hospital Anxiety and Depression Scale measure: 6 Minute Walk Test measure: Arm Curl Test measure: Laser Cursor Assisted Angle Repetition Test (LI-RATT) measure: Short Form - 12 sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Faculty of Health Sciences city: Istanbul state: Maltepe zip: 1464185881 country: Turkey lat: 41.01384 lon: 28.94966 hasResults: False
nctId: NCT06299514 id: 4754 briefTitle: RAFT-P&A Randomized Control Trial overallStatus: NOT_YET_RECRUITING date: 2024-03-10 date: 2028-12-31 date: 2029-12-31 date: 2024-03-08 date: 2024-03-12 name: Lawson Health Research Institute class: OTHER briefSummary: Atrial fibrillation (AF) is an irregular heartbeat that can cause symptoms of skipped beats, shortness of breath, stroke, or in some cases fluid in the lungs or legs. Treating AF is mostly to do with slowing the heart rate down so that the heart can get a chance to regain some energy. In some cases, slowing the heart rate is not easy to achieve as some elderly patients find it difficult to tolerate medications and suffer the side effects of such treatments. In those instances, there might be a possibility to permanently control the heart rate by implanting a pacemaker in the heart and intentionally damaging a regulatory region of the heart called the atrioventricular (AV) node. Damaging the AV node by a procedure called ablation results in the AF not being able to influence the bottom chambers (the ventricles) resulting in a slow rhythm. Therefore, if a pacemaker is implanted then the heart rate can be completely regulated by the pacemaker.
A complex pacemaker that stimulates both the right and left ventricles simultaneously (BiVP) has been used for the last decade prior to AV node ablation. More recently, a technique has been designed to reduce the number of leads in the heart, reduce procedure time and have a similar effect on the heart called Conduction System Pacing (CSP). However, this has not been directly compared to BiVP in a robust randomized control trial. There is also not enough existing evidence to show that a pace and ablate strategy is superior to optimal medical therapy. We intend to compare the efficacy of BiVP to CSP in patients who undergo AV node ablation for treating AF, in addition to comparing both pace and ablate methods to pharmacological therapy. conditions: Atrial Fibrillation conditions: Heart Failure conditions: Pacemaker conditions: Arrhythmia Atrial studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 1200 type: ESTIMATED name: Pace and Ablate name: Medication measure: Winratio measure: All-cause mortality measure: Cardiovascular mortality measure: Number of heart failure events measure: All-cause hospitalization measure: Quality of Life -Kansas City Cardiomyopathy Questionairre (KCCQ) measure: Exercise measure: Biochemical marker sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: London Health Sciences Centre - University Hospital city: London state: Ontario zip: N6A5A5 country: Canada lat: 42.98339 lon: -81.23304 facility: London Health Sciences Research city: London state: Ontario zip: N6G5A5 country: Canada name: Abbie Pardo role: CONTACT phone: 5196612111 phoneExt: 86459 email: abbie.pardo@lhsc.on.ca lat: 42.98339 lon: -81.23304 hasResults: False
nctId: NCT06299501 id: LS 2015-1199 and 2017-24 briefTitle: How Can Child Health Services Identify and Respond to Family Violence overallStatus: COMPLETED date: 2017-08-23 date: 2019-08-31 date: 2019-08-31 date: 2024-03-07 date: 2024-03-08 name: Karolinska Institutet class: OTHER name: Jane and Dan Olsson Foundation for Scientific Purposes name: Region Stockholm briefSummary: Family violence has severe impacts on children's health and development. The Child Health Services (CHS) in Sweden reaches almost 100% of families with young children and provides a unique setting to facilitate identification of family violence. This study is a three-armed randomized controlled trial (RCT) conducted to assess the effectiveness of different approaches to identify family violence within CHS. Two different approaches are tested and compared to treatment as usual; 1) information about family violence at home visit when child is newborn, and questions posed to all mothers at the 6-8-week visit; 2) information about family violence at home visit when child is newborn, and questions posed to mothers on evidence based indication. Nurses who are randomized into any of the two intervention arms receive training and supervision. The outcomes of the study are related to knowledge, attitudes, and practices around identification and support in case of family violence and number of identified cases of family violence. conditions: Family Violence conditions: Domestic Violence conditions: Intimate-partner Violence studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Three-armed study, two intervention groups and one control group primaryPurpose: HEALTH_SERVICES_RESEARCH masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 85 type: ACTUAL name: Routine questions name: Questions on evidence based indication name: Treatment as usual measure: Knowledge, attitudes and practices measure: Number of cases of family violence sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Central Child Health Care (Centrala barnhälsovården) city: Stockholm country: Sweden lat: 59.33258 lon: 18.0649 hasResults: False
nctId: NCT06299488 id: PS03 briefTitle: Combined Effects of Prunus Cerasus and Apocynum Venetum On Sleep and Anxiety in Adults With Insomnia acronym: Sip2Sleep overallStatus: COMPLETED date: 2023-04-05 date: 2023-06-01 date: 2023-07-01 date: 2024-03-07 date: 2024-03-07 name: Lakshmi Nutraceuticals LLC class: INDUSTRY name: People Science, Inc. briefSummary: Lay Summary: This study is about the effect of using a unique formula called Sip2Sleep®, a product currently available on the market which is a combination of montmorency tart cherry extract and Venetron® (Apocynum venetum leaf extract) on sleep. The purpose of this study is to evaluate the effects of taking this combination product on various aspects of sleep. This study is being conducted by People Science, and is sponsored by Lakshmi Nutraceuticals, LLC. The information we gather will help inform how people may use Sip2Sleep® to affect the quality of sleep.